Stay updated with breaking news from Sia Daneshmand. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Siamak Daneshmand, MD, discusses the results of SunRISe-1 study of TAR-200, an intravesical drug delivery system, in patients with BCG-unresponsive HR NMIBC from ESMO 2023.
Siamak Daneshmand, MD, provides closing remarks on the management of genitourinary cancers and the future of care.
Expert insight into the data presented at ESMO 2023 on the EV-302 study of enfortumab vedotin and pembrolizumab in the management of locally advanced or metastatic urothelial carcinoma.
An examination of data presented at ESMO 2023 from cohort 1 of the THOR-2 study of high-risk non–muscle invasive bladder cancer (HR NMIBC) with FGFR alterations.
Discussion on current and future treatments for BCG-unresponsive HR NMIBC presented at ESMO 2023.